Viruses: respiratory

SARS-CoV and MERS-CoV

SARS (SARS-CoV-1); MERS (Middle East respiratory syndrome coronavirus)

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

Coronaviruses that caused the 2003 SARS outbreak and Middle East respiratory syndrome. SARS-CoV-1 has not circulated since 2004; MERS occurs mainly in the Arabian Peninsula.

Infections

MERS: severe acute respiratory illness and pneumonia, sometimes with kidney failure, linked to the Arabian Peninsula. SARS: severe pneumonia; the virus has not circulated since 2004.

Signs and symptoms

Fever, cough, shortness of breath; consider MERS only with relevant travel or exposure.

Antibiotic and antimicrobial resistance

No approved antiviral, so drug resistance is not a clinical issue.

Treatment considerations

Supportive care, including oxygen and organ support; no antiviral is approved for MERS. Suspected MERS (fever and respiratory illness after travel to the Arabian Peninsula or contact with a case) needs immediate isolation and notification of the health department.

Infection control and public health

A suspected case requires immediate notification of public health and airborne and contact precautions.

Round MERS coronavirus particles near a cell, colorized transmission electron micrograph
MERS coronavirus particles, transmission electron micrograph (colorized). NIAID; public domain. Image source
Enveloped virus, schematic
Enveloped virus. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Middle East respiratory syndrome (MERS).
  2. ATS / IDSA. Community-Acquired Pneumonia in Adults guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.